Simple blood test could spot deadly bile duct cancers earlier

NCT ID NCT07176962

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study is testing a blood test that looks for DNA changes from tumors to help diagnose and manage biliary tract cancers, which are often found late and have a low survival rate. Researchers will enroll 1,800 participants with confirmed cancers to see how accurate the test is. If it works, it could lead to earlier detection and better monitoring of these aggressive cancers.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

blood test (cell-free DNA methylation liquid biopsy)

What this could lead to

If successful, this blood test could help detect biliary tract cancers earlier and monitor them more accurately, potentially improving survival rates.

What could go wrong

This is a large but still early-stage study; the test may not be accurate enough in real-world settings, and false positives or negatives could occur.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GALL BLADDER CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

bile duct cancer biliary tract cancer cholangiocarcinoma Cirrhosis, Familial, with Pulmonary Hypertension disease extrahepatic bile duct carcinoma gallbladder cancer gallbladder neoplasm hilar cholangiocarcinoma intrahepatic cholangiocarcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Renji Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai

    RECRUITING

    Shanghai, Shanghai Municipality, 200127, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••